Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
CCK-B antagonist
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "CCK-B antagonist" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .
2
2 Cited Publications
Target:
Research Areas:
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .
2
2 Cited Publications
Cat. No.: HY-106840A
Purity: 99.75%
Target:
Research Areas:
L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .
1
1 Cited Publications
Synonyms: Netazepide; YF 476; YM-220
Target:
Research Areas:
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent, highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM . Sograzepide (Netazepide; YF 476; YM-220) replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine and cloned human Gastrin/CCK-B receptors, with Ki values of 0.068, 0.62 and 0.19 nM, respectively .
Cat. No.: HY-U00360
CAS No.: 168161-71-5
Synonyms: (Rac)-Netazepide; (Rac)-YF 476; (Rac)-YM-220
Target:
Research Areas:
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.
Target:
Research Areas:
CCK-B Receptor Antagonist 2, compound 15b, is a potent and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.43 nM. CCK-B Receptor Antagonist 2 also inhibits gastrin/CCK-A activity with an IC50 of 1.82 μM .
Cat. No.: HY-19261
CAS No.: 169042-78-8
Target:
Research Areas:
T-0632 is a CCK A receptor antagonist that exhibits significant pharmacological properties in in vitro studies. T-0632 competitively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors with a K_i value of 0.24 nM, which is significantly lower than the K_i value for guinea pig CCK B receptors. T-0632 has higher selectivity in inhibiting CCK-8-stimulated pancreatic enzyme release, with an IC_50 value of 5.0 nM, which is more advantageous than L-364,718 and loxiglumide. In rabbit gallbladder smooth muscle, the antagonistic effects of T-0632 and loxiglumide are reversible, while L-364,718 shows a persistent inhibitory effect. These results indicate that T-0632 is a highly potent, reversible and more selective CCK A receptor antagonist.
Target:
Research Areas:
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.
Cat. No.: HY-U00360R
CAS No.: 168161-71-5
Synonyms: (Rac)-Netazepide (Standard); (Rac)-YF 476 (Standard); (Rac)-YM-220 (Standard)
Research Areas:
(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.
Cat. No.: HY-103357A
CAS No.: 138932-35-1
Target:
Research Areas:
LY262691 is a selective CCK-B antagonist with antipsychotic properties. LY262691 decreases the number of spontaneously active A9 and A10 dopamine cells and can be utilized in antipsychotic research .
Cat. No.: HY-129810
CAS No.: 130325-35-8
Synonyms: CAM 1028
Target:
Research Areas:
PD 135158 (CAM 1028) is a selective CCKB receptor antagonist with an IC50 of 2.8 nM against mouse cortex CCKB. PD 135158 shows anxiolytic activity .
Cat. No.: HY-19290
CAS No.: 171724-30-4
Target:
Research Areas:
S-0509 is a selective CCKB/gastrin receptor antagonist. S-0509 has a strong anti-secretion effect. S-0509 helps prevent the occurrence of duodenal ulcers .
Cat. No.: HY-106347
CAS No.: 201605-51-8
Synonyms: CR 2945
Target:
Research Areas:
Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC50 of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC50 of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity .
Cat. No.: HY-118314
CAS No.: 156672-01-4
Synonyms: PD 144598
Target:
Research Areas:
CI-1015 is a potent CCK-B receptor antagonist.
Cat. No.: HY-106356
CAS No.: 167355-22-8
Target:
Research Areas:
GV-150013 is a selective CCK-B receptor antagonist. GV-150013 has sleep aid effect .
Cat. No.: HY-100481
CAS No.: 139088-45-2
Synonyms: RPR101048
Target:
Research Areas:
RP 72540 is a selective CCK-B receptor antagonist, with IC50 values of 2.4, 1.2, and 3.8 nM for CCK-B receptors in the guinea pig cerebral cortex, rat cerebral cortex, and mouse brain, respectively. RP 72540 effectively inhibits CCK-8-induced neuronal firing and dose-dependently inhibits gastric acid secretion, making it potentially valuable in studies of acid secretion. RP 72540 is an important tool for investigating the physiological functions of CCK B receptors .
Cat. No.: HY-103357
CAS No.: 147523-65-7
Target:
Research Areas:
LY288513 is a selective non-peptide CCK-B receptor antagonist with an IC50 value of 16 nM. LY288513 produces an anxiolytic-like action in mice .
Cat. No.: HY-125610
CAS No.: 183176-50-3
Target:
Research Areas:
DA-3934 is a cholecystokinin (CCK)-B receptor antagonist. DA-3934 inhibits Pentagastrin (HY-A0261)-induced gastric acid secretion in rats .
Cat. No.: HY-118665
CAS No.: 152885-49-9
Target:
Research Areas:
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC50 values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID50, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED50, 1.7 mg/kg) .
Cat. No.: HY-P2055
CAS No.: 125598-87-0
Target:
Research Areas:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
